



**FORSKNINGSRESULTATER:
VIRKNINGERNE AF BRUG
MSTR®
(McLOUGHLIN ARVÆV RELEASE®)
PÅ KEJSERsnit
AR**

Udført den 26. oktober - 2019

på

Newcastle Clinic
4 Towers Avenue, Jesmond,
Newcastle upon Tyne,
NE2 3QE
Storbritannien

PRESSEMEDDELELSE

Jeg er glad for at kunne annoncere resultaterne af den seneste forskningsundersøgelse af virkningerne af McLoughlin Scar Tissue Release® (MSTR®) på kejsersnit.

Dette andet MSTR®-forskningsprojekt blev udført på The Newcastle Clinic, Newcastle, UK den 26. oktober 2019 med konsulent radiolog Dr. Peddada Raju MD.

En General Electric (GE) Soniq S8 ultralydsscanner blev brugt til at udføre testen på ni testpersoner med ar i kejsersnit.

Hvert emne blev forhåndsscannet og billeder optaget, herunder:

"Størrelse og dybde af arvæv

"Mængden af vaskularitet både omkring og i arvævet

MSTR® arbejde blev derefter påført i alt 15 minutter pr. forsøgsperson, som en enkelt behandling.

Umiddelbart efter MSTR®-behandling gennemgik hvert individ en ultralydsscanning efter behandlingen udført af Dr. Raju.

Alle ni forsøgspersoner blev vist at have nedsat arvæv i scanningen efter behandling. Et eksempel på forbedring var et ar, der oprindeligt blev målt til 16,6 mm før behandling. Arret blev genmålt med kun 3,6 mm efter behandling.

Et andet eksempel var et langsgående ar, der reducerede i størrelse fra 18,42 mm forbehandling til kun 8,81 mm efterbehandling.

I flere tilfælde blev der noteret en stigning i vaskulariteten, ikke kun i det omgivende væv, men faktisk også gennem arret. Interessant nok skal det bemærkes, at der i nogle tilfælde INGEN vaskularitet var til stede i præ-scanningen af det samme område.

Denne anden undersøgelse bekræfter igen, hvad der blev bemærket i den første undersøgelse af 15. juni 2019: MSTR® reducerer ikke kun arvæv, men hjælper også med at frigive de tæt bundne kollagenfibre, der udgør arvæv, for igen at tillade øget blodgennemstrømning ind i området.

Du kan læse mere om MSTR® Research Project her:

<https://www.mcloughlin-scar-release.com/research/>

Dette andet forskningsprojekt, der viser evidensbaserede resultater af MSTR®-metoden til arvævsbehandling, styrker og bekræfter vores tidligere fund fra juni 2019 og betyder, at du kan have endnu mere tillid til pålideligheden og konsekvensen af MSTR®-arbejdet.



FORSKNINGSRESULTATER

Oversigt

Af de ni ar, vi undersøgte, var syv tværgående kejsersnit, et var abdominoplastik, et var abdominal hysterektomi.

Finansiering

Denne undersøgelse blev udelukkende finansieret af offentlige og private bidrag.

Forskningsdeltagere

Forskningsdeltagere blev fundet via forespørgsler på sociale medier.

De specifikke mål for ultralydsbilleddannelse ved brug af MSTR®-teknik er:

- Ændringer i arvævet's størrelse og dybde
- Ændringer i blodgennemstrømningen (vaskularitet) i tilstødende væv, der omgiver arvævet
- Ændringer i blodgennemstrømningen (vaskularitet) i selve arvævet

Forskerholdet:

Dr. Peddada Raju - Konsulent radiolog

Paula Esson - Forskningsforbindelse, MSTR® praktiserende læge og Dr. Rajus assistent

Silke Lauth - Forskningsassistent, MSTR® practitioner

Alastair McLoughlin - skaberen af MSTR®, ledende praktiserende læge

Mødested:

Newcastle Clinic

4 Towers Avenue, Jesmond,

Newcastle upon Tyne,

NE2 3QE

Storbritannien

Hypotese

På grund af den stigende evidens fra hundredvis af registrerede casestudier fra en lang række post-kirurgiske og traumesår ar, der viser ekstremt gode og konsistente ændringer i arvæv, antager vi, at disse ændringer skyldes adskillelsen af den tæt bundne kollagenmatrix og substrat fundet på arvævssteder ved hjælp af MSTR®-metoden.

Vi antager, at blod- og lymfestrømmen øges gennem og omkring arvævsstedet.

De allerede observerede overfladeændringer i arvævstæthed og fibrose antyder muligheden for, at kollagenfibre i arvæv er genjusteret og danner en mere naturlig justering - som findes i sundt uudslettet væv.

Vi antager også, at vedhæftede fasciestrukturer omkring arret også frigives.

Ofte bemærkes sensoriske ændringer og forbedring af nervetransmission også af casestudiefeedback.

Vi har også casestudiebeviser for, at Range-of-Motion-tests indikerer forbedret funktionalitet af rygsøjlen og lemmerne. Ændringer og reduktion af lændesmerter kan for eksempel være en anden fordel ved C-sektionsbehandling.

Metode

" Vi gennemførte forskningsundersøgelsen om ni emner.

" Et patientspørgeskema blev brugt til at indsamle generel information om patienten. Vi inkluderede også specifikke spørgsmål vedrørende selve kejsersnittet: når operationen fandt sted, alle fysiske udslag, arret frembringer, og alle følelsesmæssige eller psykologiske effekter, der måtte opleves på grund af arret.

" En ultralydsscanning før behandling blev udført af Dr. Peddada Raju. Billeder blev optaget via GE Soniq S8 ultralydsscanner. Arvævsmålinger blev også registreret.

" MSTR®-behandling blev udført på mavearret i 15 minutter i alt.

I løbet af 15 minutters behandling blev der inkluderet to pauser på hver to minutter. Dette reducerede den faktiske MSTR®-behandling til ca. 11 minutters praktisk tid i alt.

" En efterbehandling ultralydsscanning og arvævsmålinger udført af Dr Raju blev optaget.

Resultater




EMNE ID	DD	LF	NC	PE	CW	AB	KH	JC	SS
Alder	46 år. 7 mdr.	37 år. 3 mdr.	49 år. 1 måned.	49 år. 9 mdr.	50 år. 3 mdr.	53 år. 5 mdr.	42 år. 1 måned.	36 år. 5 mdr.	33 år. 7 mdr.
Antal C - sektioner	2	1	1 abdominal hysterektomi	1	2	3	1	1 abdomino plastik	1
Alder af kejsersnit	13 år + 11 år	5 måneder	3 år	23 år	20 år + 18 år	21 år, 18 år, 17 år	3 år	1 år	1 år
Type Nødsituation = E Planlagt =P	E+P	P	P	E	P+E	E+P+P	E	P	P
Værdier:									
Pre tx Dybste	19,3 mm	14,21 mm	11,35 mm	*	19,15 mm	17,12 mm	7,05 mm	10,14 mm	9,3 mm
Post tx Dybste	10,7 mm	7,26 mm	9,95 mm	*	14,29 mm	15,79 mm	5,88 mm	7,85 mm	7,56 mm
Pre tx Langsgående	9,4 mm	10,03 mm	6,73 mm	18,42 mm	15,14 mm	14,28 mm	11,05 mm	8,08 mm	5,34 mm
Post tx Langsgående	6,7 mm	5,28 mm	6,55 mm	8,81 mm	8,4 mm	8,25 mm	10,77 mm	7,62 mm	4,86 mm
Pre tx Dyb	16,6 mm	11,95 mm	11,22 mm	*	16,14 mm	10,99 mm	5,6 mm	7,78 mm	6,6 mm
Post tx Dyb	3,6 mm	5,11 mm	5,13 mm	*	10,62 mm	9,0 mm	3,6 mm	7,14 mm	4,39 mm
Pre tx Tværgående	9,9 mm	9,72 mm	7,2 mm	14,97 mm	12,78 mm	13,52 mm	8,95 mm	5,84 mm	3,36 mm**
Post tx Tværgående	7,3 mm	5,71 mm	4,65 mm	11,34 mm	8,58 mm	11,77 mm	6,36 mm	4,02 mm	5,7 mm**

*
= Det var ikke muligt at foretage nøjagtige målinger for disse områder.

**
= En tilsyneladende unormal læsning, hvor arvæv syntes at øges. Målingen efter behandlingen blev kontrolleret tre gange af Dr. Raju for at sikre nøjagtigheden. Efter konsultation med Dr. Raju konkluderede vi, at en stigning i lymfevæske i området kan have været skyld i den tilsyneladende større armåling. På ultralydsbilledet kan du se to små sorte områder (væske) forbehandling, som er forsvundet i efterbehandlingsbilledet.

SAMLEDE ARMÅLINGER OG PROCENT AF ÆNDRING:








	Forbehandling	Efterbehandling	Procentvis reduktion
dybeste	107,62 mm	79,28 mm	26,33 %
langsgående	98,47 mm	67,24 mm	31,72 %
dyb	86,88 mm	48,59 mm	44,07 %
tværgående	86,24 mm	65,7 mm	23,82 %
Samlede mål	379,21 mm	260,81 mm	31,22 %










Emne DD Forbehandling		Efterbehandling
dybeste	NEWCASTLE CLINIC 26/10/19 09:40:24 PPJ DD261019, 20/03/73 MI 1.0 TIs 0.5 ML6-15 MSK Gen CAESAREAN SCAR DEEPEST  1 L 19.30 mm FR 16 AO% 100 CHI 12.0 Frq 46 Gn 3/3 S/A 3/3 Map F/0 D 5.0 DR 69	NEWCASTLE CLINIC 26/10/19 10:06:42 PPJ DD261019, 20/03/73 MI 1.0 TIs 0.5 ML6-15 MSK Gen CAESAREAN SCAR POST TREATMENT DEEPEST  1 L 10.70 mm FR 16 AO% 100 CHI 12.0 Frq 46 Gn 3/3 S/A 3/3 Map F/0 D 5.0 DR 69
langsgående	NEWCASTLE CLINIC 26/10/19 09:42:35 PPJ DD261019, 20/03/73 MI 1.0 TIs 0.5 ML6-15 MSK Gen CAESAREAN SCAR  1 L 9.90 mm FR 16 AO% 100 CHI 12.0 Frq 46 Gn 3/3 S/A 3/3 Map F/0 D 5.0 DR 69	NEWCASTLE CLINIC 26/10/19 10:15:14 PPJ DD261019, 20/03/73 MI 1.0 TIs 0.5 ML6-15 MSK Gen CAESAREAN SCAR POST TREATMENT  1 L 6.70 mm FR 16 AO% 100 CHI 12.0 Frq 46 Gn 3/3 S/A 3/3 Map F/0 D 5.0 DR 69
dyb	NEWCASTLE CLINIC 26/10/19 09:41:25 PPJ DD261019, 20/03/73 MI 1.0 TIs 0.5 ML6-15 MSK Gen CAESAREAN SCAR DEEP  1 L 15.60 mm FR 16 AO% 100 CHI 12.0 Frq 46 Gn 3/3 S/A 3/3 Map F/0 D 5.0 DR 69	NEWCASTLE CLINIC 26/10/19 10:07:45 PPJ DD261019, 20/03/73 MI 1.0 TIs 0.5 ML6-15 MSK Gen CAESAREAN SCAR POST TREATMENT DEEP  1 L 3.60 mm FR 16 AO% 100 CHI 12.0 Frq 46 Gn 3/3 S/A 3/3 Map F/0 D 5.0 DR 69
tværgående	NEWCASTLE CLINIC 26/10/19 09:46:29 PPJ DD261019, 20/03/73 MI 1.0 TIs 0.5 ML6-15 MSK Gen CAESAREAN SCAR  1 L 9.90 mm FR 16 AO% 100 CHI 12.0 Frq 46 Gn 3/3 S/A 3/3 Map F/0 D 5.0 DR 69	NEWCASTLE CLINIC 26/10/19 10:09:30 PPJ DD261019, 20/03/73 MI 1.0 TIs 0.5 ML6-15 MSK Gen CAESAREAN SCAR POST TREATMENT  1 L 7.30 mm FR 16 AO% 100 CHI 12.0 Frq 46 Gn 3/3 S/A 3/3 Map F/0 D 5.0 DR 69
vaskularitet	NEWCASTLE CLINIC 26/10/19 09:46:29 PPJ DD261019, 20/03/73 MI 0.8 TIs 0.9 ML6-15 MSK Gen CAESAREAN SCAR  FR 3 AO% 100 CHI 12.0 Frq 46 Gn 7.0 2-PDI 7.7 Frq 28.0 L/A 2/5 PRF 1.0 WF 131 4-S/P 1/16	NEWCASTLE CLINIC 26/10/19 10:14:16 PPJ DD261019, 20/03/73 MI 0.8 TIs 0.9 ML6-15 MSK Gen CAESAREAN SCAR POST TREATMENT  FR 4 AO% 100 CHI 12.0 Frq 46 Gn 5.0 2-PDI 7.7 Frq 24.0 L/A 2/5 PRF 0.4 WF 52 4-S/P 1/16

Emne LF Forbehandling		Efterbehandling
dybeste		
langsgående		
dyb		
tværgående		
vaskularitet		

Emne NC Forbehandling	Efterbehandling
dybeste 	
langsgående 	
dyb 	
tværgående 	
vaskularitet 	

Emne PE Forbehandling		Efterbehandling
dybeste	INTET BILLEDE OPTAGET	INTET BILLEDE OPTAGET
langsgående		
dyb	INTET BILLEDE OPTAGET	INTET BILLEDE OPTAGET
tværgående		
vaskularitet		

Emne CW Forbehandling		Efterbehandling
dybeste	NEWCASTLE CLINIC 26/10/19 11:38:07 PPJ CW200769, 20/07/69 MI 1.2 Tls 0.1 MSL-15 MSK Gen CAESAREAN SECTION  1 L 10.15 mm FR 21 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69	NEWCASTLE CLINIC 26/10/19 12:06:23 PPJ CW200769, 20/07/69 MI 1.2 Tls 0.1 MSL-15 MSK Gen CAESAREAN SECTION POST TREATMENT  1 L 14.29 mm FR 21 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69
langsgående	NEWCASTLE CLINIC 26/10/19 11:40:33 PPJ CW200769, 20/07/69 MI 1.2 Tls 0.1 MSL-15 MSK Gen CAESAREAN SECTION  1 L 15.14 mm FR 21 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69	NEWCASTLE CLINIC 26/10/19 12:08:49 PPJ CW200769, 20/07/69 MI 1.2 Tls 0.1 MSL-15 MSK Gen CAESAREAN SECTION POST TREATMENT  1 L 8.40 mm FR 21 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69
dyb	NEWCASTLE CLINIC 26/10/19 11:40:44 PPJ CW200769, 20/07/69 MI 1.2 Tls 0.1 MSL-15 MSK Gen CAESAREAN SECTION  1 L 16.14 mm FR 21 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69	NEWCASTLE CLINIC 26/10/19 12:08:05 PPJ CW200769, 20/07/69 MI 1.2 Tls 0.1 MSL-15 MSK Gen CAESAREAN SECTION POST TREATMENT  1 L 10.62 mm FR 21 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69
tværgående	NEWCASTLE CLINIC 26/10/19 11:40:12 PPJ CW200769, 20/07/69 MI 1.2 Tls 0.1 MSL-15 MSK Gen CAESAREAN SECTION  1 L 12.78 mm FR 21 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69	NEWCASTLE CLINIC 26/10/19 12:08:36 PPJ CW200769, 20/07/69 MI 1.2 Tls 0.1 MSL-15 MSK Gen CAESAREAN SECTION POST TREATMENT  1 L 8.58 mm FR 21 AO% 100 CHI Frq 12.0 Gn 46 S/A 3/3 Map F/0 D 3.0 DR 69
vaskularitet	NEWCASTLE CLINIC 26/10/19 11:41:35 PPJ CW200769, 20/07/69 MI 1.1 Tls 0.8 MSL-15 MSK Gen CAESAREAN SECTION  FR 9 AO% 100 CHI Frq 12.0 Gn 46 D 3.0 PRF 7.7 L/A 2/5 PRF 1.0 WF 131 S/P 1/16	NEWCASTLE CLINIC 26/10/19 12:11:58 PPJ CW200769, 20/07/69 MI 1.1 Tls 0.8 MSL-15 MSK Gen CAESAREAN SECTION POST TREATMENT  FR 8 AO% 100 CHI Frq 12.0 Gn 46 D 3.0 PRF 7.7 L/A 2/5 PRF 1.0 WF 131 S/P 1/16

Emne AB Forbehandling		Efterbehandling
dybeste	NEWCASTLE CLINIC 26/10/19 11:58:28 PPJ AB1210566, 12/05/66 MI 1.1 Tls 0.1 MLE-15 MSK Gen CAESAREAN SECTION SCAR  1 L 17.12 mm	NEWCASTLE CLINIC 26/10/19 12:24:54 PPJ AB1210566, 12/05/66 MI 1.2 Tls 0.1 MLE-15 MSK Gen SCAR POST TREATMENT  1 L 15.79 mm
langsgående	NEWCASTLE CLINIC 26/10/19 12:00:43 PPJ AB1210566, 12/05/66 MI 1.1 Tls 0.1 MLE-15 MSK Gen CAESAREAN SECTION SCAR  1 L 14.28 mm	NEWCASTLE CLINIC 26/10/19 12:27:31 PPJ AB1210566, 12/05/66 MI 1.2 Tls 0.1 MLE-15 MSK Gen SCAR POST TREATMENT  1 L 8.25 mm
dyb	NEWCASTLE CLINIC 26/10/19 11:59:41 PPJ AB1210566, 12/05/66 MI 1.1 Tls 0.1 MLE-15 MSK Gen CAESAREAN SECTION SCAR  1 L 10.99 mm	NEWCASTLE CLINIC 26/10/19 12:26:16 PPJ AB1210566, 12/05/66 MI 1.2 Tls 0.1 MLE-15 MSK Gen SCAR POST TREATMENT  1 L 9.00 mm
tværgående	NEWCASTLE CLINIC 26/10/19 12:00:15 PPJ AB1210566, 12/05/66 MI 1.1 Tls 0.1 MLE-15 MSK Gen CAESAREAN SECTION SCAR  1 L 13.52 mm	NEWCASTLE CLINIC 26/10/19 12:26:58 PPJ AB1210566, 12/05/66 MI 1.2 Tls 0.1 MLE-15 MSK Gen SCAR POST TREATMENT  1 L 11.77 mm
vaskularitet	NEWCASTLE CLINIC 26/10/19 12:02:10 PPJ AB1210566, 12/05/66 MI 1.0 Tls 0.9 MLE-15 MSK Gen CAESAREAN SECTION SCAR 	NEWCASTLE CLINIC 26/10/19 12:28:26 PPJ AB1210566, 12/05/66 MI 1.1 Tls 0.8 MLE-15 MSK Gen SCAR POST TREATMENT 

Emne KH Forbehandling		Efterbehandling
dybeste	NEWCASTLE CLINIC 26/10/19 13:45:13 PPJ KH100977, 10/09/77 MI 1.2 Tls 0.1 MSL-15 MSK Gen CAESAREAN SECTION SCAR 1 L 7.05 mm	NEWCASTLE CLINIC 26/10/19 14:14:47 PPJ KH100977, 10/09/77 MI 1.2 Tls 0.1 MSL-15 MSK Gen POST TREATMENT SCAR 1 L 5.88 mm
langsgående	NEWCASTLE CLINIC 26/10/19 13:49:36 PPJ KH100977, 10/09/77 MI 1.2 Tls 0.1 MSL-15 MSK Gen CAESAREAN SECTION SCAR 1 L 11.05 mm	NEWCASTLE CLINIC 26/10/19 14:16:07 PPJ KH100977, 10/09/77 MI 1.2 Tls 0.1 MSL-15 MSK Gen POST TREATMENT SCAR 1 L 10.77 mm
dyb	NEWCASTLE CLINIC 26/10/19 13:49:36 PPJ KH100977, 10/09/77 MI 1.2 Tls 0.1 MSL-15 MSK Gen CAESAREAN SECTION SCAR 1 L 5.60 mm	NEWCASTLE CLINIC 26/10/19 14:15:10 PPJ KH100977, 10/09/77 MI 1.2 Tls 0.1 MSL-15 MSK Gen POST TREATMENT SCAR 1 L 3.60 mm
tværgående	NEWCASTLE CLINIC 26/10/19 13:50:40 PPJ KH100977, 10/09/77 MI 1.2 Tls 0.1 MSL-15 MSK Gen CAESAREAN SECTION SCAR 1 L 8.95 mm	NEWCASTLE CLINIC 26/10/19 14:15:38 PPJ KH100977, 10/09/77 MI 1.2 Tls 0.1 MSL-15 MSK Gen POST TREATMENT SCAR 1 L 6.36 mm
vaskularitet	NEWCASTLE CLINIC 26/10/19 13:50:40 PPJ KH100977, 10/09/77 MI 1.1 Tls 0.8 MSL-15 MSK Gen CAESAREAN SECTION SCAR 1 L 8.95 mm	NEWCASTLE CLINIC 26/10/19 14:15:04 PPJ KH100977, 10/09/77 MI 1.1 Tls 0.8 MSL-15 MSK Gen POST TREATMENT SCAR 1 L 6.36 mm

Emne JC Forbehandling		Efterbehandling
dybeste		
langsgående		
dyb		
tværgående		
vaskularitet		

	Emne SS Forbehandling	Efterbehandling
dybeste		
langsgående		
dyb		
tværgående		
vaskularitet		

Samlet længde af alle ar målt forbehandling = 379,21 mm

Samlet længde af alle ar målt efter behandling = 260,81 mm

Samlet reduktion i alt målt arvæv = 31,22 %

Konklusion

Efter en enkelt 15 minutters MSTR®-behandling pr. forsøgsperson og en øjeblikkelig genscanning af området var der en observerbar reduktion i mængden af målt arvæv for de ni forsøgspersoner.

Den samlede reduktion af arvæv er beregnet til 31,22%, hvilket er en væsentlig forbedring og viser, at MSTR® reducerer arvæv i en enkelt behandling.

Resultaterne af denne forskning forstærker også tidligere forskningsresultater (juni 2019), hvor den samlede reduktion af ar blev målt til 33,55 %. Denne anden undersøgelse viser nu de konsekvent høje og pålidelige arvævsresponsrater med MSTR®-behandling.

Alastair McLoughlin
www.McLoughlin-Scar-Release.com

© Alastair McLoughlin

Nedenfor er rapporterne fra The Newcastle Clinic, udarbejdet af Dr. Peddada Raju fra The Newcastle Clinic
- UK, dateret den 30. oktober 2019.

Ref: PPJR/SR

Scan Date: 26.10.19

30th October 2019



Mr Alastair McLoughlin

Germany

Dear Mr McLoughlin

Re: D D DOB: 20.03.73

Ultrasound Examination – Anterior abdominal wall

Clinical Details: History of caesarean section scar in the lower abdominal wall.

Report: The anterior abdominal wall scar in the subcutaneous fat was barely visible and was difficult to measure. The approximate deepest dimension of the scar before treatment is 19.3mm but after the treatment decreased to 10.7mm.

The approximate depth of the scar which was measured just right of the midline (right lateral) was approximately 16.6mm before treatment but after treatment the approximate depth just right of midline decreased to approximately 3.6mm.

The approximate dimensions of the scar in longitudinal and transverse dimensions is 9.4mm x 9.9mm respectively before treatment but following treatment the scar tissue measures approximately 6.7mm x 7.3mm in maximum approximate longitudinal and transverse dimensions respectively. There was no evidence of any vascularity noted in the scar or around the scar before treatment but following treatment, blood supply around the scar was noted especially in the subcutaneous adipose tissue but there was no evidence of any vascularity noted in the scar following treatment.

Yours sincerely

Dr. P P J Raju
Consultant Radiologist

Newcastle Clinic Limited
4 Towers Avenue
Jesmond
Newcastle Upon Tyne
NE2 3QE
t: 0191 281 2636
f: 0191 281 2393
reception@newcastleclinic.co.uk

Registered by the Care Quality Commission No: NO10000008
Company Registration Number: 5843596
Registered Office: Oakapple House, 1 John Charles Way, Leeds, LS12 6QA

Ref: PPJR/SR

Scan Date: 26.10.19

30th October 2019



Mr Alastair McLoughlin

Germany

Dear Mr McLoughlin

Re: P E DOB: 17.01.70

Ultrasound Examination – Anterior abdominal wall

Clinical Details: Caesarean section noted.

Report: On ultrasound examination, scar tissue measures approximately 18.4mm x 14.9mm in maximum approximate longitudinal and transverse dimensions respectively before treatment but following treatment, there was a decrease in the dimensions of the scar tissue. The scar tissue measures approximately 8.8mm x 11.3mm in maximum longitudinal and transverse dimensions respectively.

Before treatment, there was no evidence of any vascularity noted in and around the scar but following treatment, there was vascularity noted around the scar in the anterior fascia covering the anterior aspect of the rectus abdominus muscle.

Yours sincerely

Dr. P P J Raju
Consultant Radiologist

Newcastle Clinic Limited
4 Towers Avenue
Jesmond
Newcastle Upon Tyne
NE2 3QE
t: 0191 281 2636
f: 0191 281 2393
reception@newcastleclinic.co.uk

Registered by the Care Quality Commission No: NO1000008
Company Registration Number: 5843596
Registered Office: Oakapple House, 1 John Charles Way, Leeds, LS12 6QA

Ref: PPJR/SR

Scan Date: 26.10.19

30th October 2019



Mr Alastair McLoughlin

Germany

Dear Mr McLoughlin

Re: C W DOB: 20.07.69

Ultrasound Examination – Anterior abdominal wall

Clinical Details: Caesarean section noted.

Report: There is evidence of lower abdominal wall caesarean section scar. The deepest dimensions of the anterior abdominal wall scar in the region of the caesarean section measures approximately 19.5mm before treatment but following treatment, the deepest dimension of the scar decreased to approximately 14.2mm only.

The approximate depth of the scar before treatment was 16.1mm especially to the right of the midline but following treatment, the approximate depth of the scar decreased to 10.6mm.

Approximate dimensions of the scar are 15.1mm x 12.7mm in maximum longitudinal and transverse dimensions respectively before treatment but following treatment, the approximate dimensions of the scar are 8.4mm x 8.5mm in maximum longitudinal and transverse dimensions respectively.

On power Doppler interrogation there was minimal vascularity noted around the scar, but no evidence of any vascularity in the scar tissue. Following treatment, there was increase in the vascularity around the scar tissue but again, no evidence of any abnormal vascularity noted in the scar tissue following treatment.

Yours sincerely

Dr. P P J Raju
Consultant Radiologist

Newcastle Clinic Limited
4 Towers Avenue
Jesmond
Newcastle Upon Tyne
NE2 3QE

T: 0191 281 2636
F: 0191 281 2393

reception@newcastleclinic.co.uk

Registered by the Care Quality Commission No: NO10000008

Company Registration Number: 5843596

Registered Office: Oakapple House, 1 John Charles Way, Leeds, LS12 6QA



Ref: PPJR/SR

Scan Date: 26.10.19

30th October 2019

Mr Alastair McLoughlin

Germany

Dear Mr McLoughlin

Re: A B DOB: 12.05.66

Ultrasound Examination – Anterior abdominal wall

Clinical Details: Caesarean section noted.

Report: There is evidence of healed scar noted in the suprapubic region in the lower abdominal wall related to healed caesarean section scar.

Approximately deepest dimension of the scar before treatment is 17mm which decreased to 15.7mm following treatment. The depth of the scar just right of midline is approximately 10.9mm which decreased to 9mm following treatment.

Approximate dimensions of the scar are 14.2mm x 13.5mm and maximum longitudinal and transverse dimension respectively before treatment but following treatment, the approximate dimensions are 8.2mm x 11mm and maximum longitudinal and transverse dimensions respectively.


There was no evidence of any vascularity noted around the scar before treatment but following treatment, there was evidence of minimal vascularity noted in the scar and around the scar on power Doppler interrogation.

Yours sincerely

Dr. P P J Raju
Consultant Radiologist

Newcastle Clinic Limited
4 Towers Avenue
Jesmond
Newcastle Upon Tyne
NE2 3QE
t: 0191 281 2636
f: 0191 281 2393
reception@newcastleclinic.co.uk

Registered by the Care Quality Commission No: NO10000008
Company Registration Number: 5843596
Registered Office: Oakapple House, 1 John Charles Way, Leeds, LS12 6QA



Ref: PPJR/SR

Scan Date: 26.10.19

30th October 2019

Mr Alastair McLoughlin

Germany

Dear Mr McLoughlin

Re: K H DOB: 10.09.77

Ultrasound Examination – Anterior abdominal wall

Clinical Details: Caesarean section noted.

Report: The deepest dimension of the scar in the midline is approximately 7mm before treatment but following treatment, the deepest dimension of the scar decreased to approximately 5.8mm.

The dimension of the scar especially in its maximum depth just right of midline is approximately 5.6mm before treatment but following treatment, this dimension decreased to approximately 3.6mm.

The approximate dimensions of the scar are 8.9mm x 11mm in maximum transverse and longitudinal dimensions respectively before treatment but following treatment, the approximate dimensions of the scar are 6.3mm x 10.7mm and maximum transverse and longitudinal dimensions respectively.

On power Doppler interrogation, there was no evidence of any vascularity noted in the scar or around the scar but following treatment, there was evidence of vascularity noted around the scar including mildly increased vascularity in the scar itself. Please note that this is a deep fascial scar and there was no evidence of any subcutaneous scar tissue especially in the subcutaneous fat on the ultrasound examination.

Yours sincerely

Dr. P P J Raju
Consultant Radiologist

Newcastle Clinic Limited
4 Towers Avenue
Jesmond
Newcastle Upon Tyne
NE2 3QE
t: 0191 281 2636
f: 0191 281 2393
reception@newcastleclinic.co.uk

Registered by the Care Quality Commission No: NO1000008
Company Registration Number: 5843596
Registered Office: Oakapple House, 1 John Charles Way, Leeds, LS12 6QA



Ref: PPJR/LE

Scan Date: 26.10.19

5th November 2019

Mr Alastair McLoughlin

Germany

Dear Mr McLoughlin

Re: J C D.O.B. 10.05.83

Ultrasound Examination – Anterior abdominal wall

Clinical Details: Tummy Tuck scar noted.

Report: The deepest dimension of the scar is approximately 10 mm before treatment. Treatment and the deepest dimension decreased to approximately 7.8 mm. The approximate dimensions of the scar just right of midline is 7.7 mm in its maximum depth which decreased to approximately 7.1 mm following treatment.

The dimensions of the scar tissue is approximately 8 mm x 5.8 mm in maximum longitudinal and transverse dimensions respectively before treatment.

After treatment, the approximate dimensions of scar are 7.6 mm x 4 mm in maximum longitudinal and transverse dimensions respectively.

Before treatment, there was no evidence of vascularity in the scar tissue and there was no evidence of any vascularity noted around the scar tissue on power Doppler interrogation. Following treatment, there was increased vascularity noted in the scar and around the scar.

Yours sincerely

Dr. P P J Raju
Consultant Radiologist

Newcastle Clinic Limited
4 Towers Avenue
Jesmond
Newcastle Upon Tyne
NE2 3QE
t: 0191 281 2636
f: 0191 281 2393
reception@newcastleclinic.co.uk

Registered by the Care Quality Commission No: NO10000008
Company Registration Number: 5843596
Registered Office: Oakapple House, 1 John Charles Way, Leeds, LS12 6QA



Ref: PPJR/SR

Scan Date: 26.10.19

30th October 2019

Mr Alastair McLoughlin

Germany

Dear Mr McLoughlin

Re: S S DOB: 13.03.86

Ultrasound Examination – Anterior abdominal wall

Clinical Details: Caesarean section noted.

Report: Before treatment, the depressed dimension of the scar tissue is approximately 9.3mm which decreased to approximately 7.5mm following treatment of the scar. The approximate dimensions of the scar just right of midline is 6.3mm before treatment but following treatment, the approximate dimensions of the scar is 4.4mm.

The approximate measurements of the scar is 5.3mm x 3.4mm in maximum longitudinal and transverse dimension respectively following treatment, the approximate dimensions of the scar of 4.8mm x 5.7mm in maximum longitudinal and transverse dimensions respectively.

On power Doppler interrogation, there was no evidence of any vascularity noted in and around the scar but following treatment, there was evidence of vascularity noted around the scar which was essentially noted just superficial and anterior to the scar in the subcutaneous soft tissues.

Yours sincerely

Dr. P P J Raju
Consultant Radiologist

Newcastle Clinic Limited
4 Towers Avenue
Jesmond
Newcastle Upon Tyne
NE2 3QE
t: 0191 281 2636
f: 0191 281 2393
reception@newcastleclinic.co.uk

Registered by the Care Quality Commission No: ND1000008
Company Registration Number: 5843596
Registered Office: Oakapple House, 1 John Charles Way, Leeds, LS12 6QA

